When does atezolizumab’s patent exclusivity end?
The exact “exclusivity” end date depends on which legal protection you mean (US patent term, marketing exclusivity, or additional protections like pediatric extensions) and which country. The key practical point is that atezolizumab (Tecentriq) is protected by a mix of patents and regulatory exclusivity, so different dates can apply.
What parts of “exclusivity” can create different end dates?
In practice, people tracking an antibody like atezolizumab usually have to separate these concepts:
- Patent term (including patent-by-patent expirations)
- Regulatory marketing exclusivity (where applicable)
- Additional extensions (for example, pediatric or other statutory extensions, depending on jurisdiction)
Because a biologic can have many patents covering different aspects (molecule, formulations, manufacturing), “the” exclusivity date is often not a single day but a set of expirations.
How do biosimilar and interchangeable-drug timelines typically work?
For biosimilars in the US, entry timing is driven by the earlier of:
- Expiration of relevant biologics-related exclusivities, and
- Patent expirations and any resulting litigation stay periods
So even if some regulatory exclusivity lapses earlier, biosimilar launches can still be blocked by patent coverage unless those patents expire or are cleared through the regulatory pathway.
Why you might see conflicting timelines in different sources
Search results often disagree because:
- One source reports earliest patent expiry, another reports longest patent expiry.
- Some sources track “regulatory exclusivity,” others track “patent protection.”
- Dates can differ by country (US vs EU vs UK), and by indication (some exclusivities are indication-specific).
To get the correct timeline, you typically need to specify jurisdiction and whether you mean earliest biosimilar entry eligibility or the latest patent that still blocks it.
What I need to give you a precise end date
Tell me:
1) Which country’s timeline you want (US, EU/EMA, UK, other), and
2) Whether you mean the first eligible biosimilar entry date or the last patent/exclusivity date, and
3) (If relevant) whether you care about a specific indication (for example, NSCLC, urothelial cancer, etc.).
With that, I can map the correct exclusivity/patent milestones in the right jurisdiction and format.